Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oregovomab + Chemotherapy in Advanced Ovarian Cancer
NCT04498117Phase 3Active, not recruiting
- Sponsor
- CanariaBio
- Start
- Aug 2020
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of oregovomab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by CanariaBio. Started Aug 2020; status: active, not recruiting.
02
Drugs
oregovomab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04498117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04498117.